Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bobylev

Showing results (211-220 of 214) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 214 results.
Allergy|October 8, 2024
Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE studyR Soegiharto, M Alizadeh Aghdam, J A Sørensen, et al.
JAMA Dermatology|July 17, 2024
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for DiscontinuationReineke Soegiharto, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 6, 2025
Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicentre Real-World StudyReineke Soegiharto, Esther Van der Wind, Mehran Alizadeh Aghdam, et al.
Urologiia (Moscow, Russia : 1999)|November 20, 2024
[Automated system for supporting medical decision-making in the treatment of patients with renal parenchyma neoplasms first experience of using the web-platform Sechenov.AI_nephro results of multicenter testing]A Zholdubaev A, V Glybochko P, G Alyaev Yu, et al.
Pageof 22

Showing results (211-220 of 214) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 214 results.
Allergy|October 8, 2024
Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE studyR Soegiharto, M Alizadeh Aghdam, J A Sørensen, et al.
JAMA Dermatology|July 17, 2024
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for DiscontinuationReineke Soegiharto, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|May 6, 2025
Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicentre Real-World StudyReineke Soegiharto, Esther Van der Wind, Mehran Alizadeh Aghdam, et al.
Urologiia (Moscow, Russia : 1999)|November 20, 2024
[Automated system for supporting medical decision-making in the treatment of patients with renal parenchyma neoplasms first experience of using the web-platform Sechenov.AI_nephro results of multicenter testing]A Zholdubaev A, V Glybochko P, G Alyaev Yu, et al.
Pageof 22